Standard Drug Discovery and Development

$1 to $2 billion

Cost of a new drug development

10 to 15 years

To develop a new drug

1:10k

Success rate

We can reduce those numbers to

$250k – $50M

Cost of a new drug development

4 to 5 years

To develop a new drug

3:10

Success rate

OUR APPROACH

Artificial Intelligence

Propietary Databases of Chemical Structures

Scientific Expertise

Our Directions of Work

Proprietary pipeline

Proprietary pipeline

PARTNERSHIP

Our performance indicators

12%

of our performed projects have
reached Clinical Phase 2

29%

of our projects have a positive
in vitro lead

We cooperate with

SOM Biotech in the media

LATEST NEWS

AI-Driven Drug Repositioning & Repurposing
SOM Biotech at the “AI-Driven Drug Repositioning & Repurposing” Event
April 6, 2021

SOM Biotech will attend the “AI-Driven Drug Repositioning & Repurposing” digital congress on April 20th – 21st. Organized by Hanson Wade, the “AI-Driven Drug Repositioning & Repurposing” event aims at featuring real-life case studies and experiences from companies that prove that introducing artificial intelligence in drug repurposing and repositioning is ...

Bio-Europe Spring 2021
SOM Biotech to participate at the BIO-Europe Spring
March 1, 2021

SOM Biotech announces its participation in the BIO-Europe Spring 2021 partnering event on March 22nd – 25th, which will take place digitally due to the pandemic situation. Organized by the EBD Group, a global partnering event organizer, the BIO-Europe Spring event attracts leading decision-makers not only from the traditional pharma ...

Rare Disease Day 2021
February 24, 2021

On the 28th of February, we’ll be celebrating Rare Disease Day 2021. We are proud to work on rare diseases. For SOM Biotech, rare diseases are a challenge that drives us to care for unique people with extraordinary strength. Rare is UNIQUE, rare is EXTRAORDINARY, rare is STRONG!!! We encourage ...

SOM Biotech ends 2020 with an advanced and robust pipeline
SOM Biotech at Chiba Healthcare Business Forum 2021
February 1, 2021

SOM Biotech will attend the “Chiba Global Healthcare Business Forum 2021” on February 3rd – 4th, which will take place digitally due to the pandemic situation. Organized by the Japanese External Trade Association, the Chiba Healthcare Business Forum attracts the most advanced academic and research institutions as well as healthcare ...

HAPPY END OF THE 2020!
December 21, 2020

We wish a happy and healthy holiday to everyone who has trusted SOM Biotech during this challenging year marked by the Covid-19 pandemic. Thank you, especially to the entire team, whose hard work has been essential in such a demanding year. We wish you a safe and Merry Christmas and ...

SOM Biotech ends a notable year 2020
SOM Biotech ends 2020 with an advanced and robust pipeline that strengthens the company’s future
December 21, 2020

SOM Biotech ends the notable year 2020 with relevant advances in its pipeline. The company started 2020 with positive results from the Phase 2a proof-of-concept to evaluate the safety and efficacy of SOM3355, an inhibitor of the Vesicular Monoamine Transporter-2 (VMAT2), in Huntington´s disease (HD) patients with chorea. The clinical ...

SOM Biotech at the BIO- Partnering JPM Virtual Event 2021
December 18, 2020

SOM Biotech announces its participation at the BIO-Partnering at JP Morgan Healthcare Conference 2021, being held virtually on January 11th – 15th. The conference, a leading virtual partnering and business development initiative for the biotechnology industry organized by Biotechnology Innovation Organization, provides a One-on-One partnering platform to give companies access ...

A pioneering real AI drug discovery technology
European Biotechnology: “A pioneering real AI drug discovery technology”
November 26, 2020

European Biotechnology Life Science and Industry Magazine published the article “A pioneering real AI drug discovery technology” describing the approach of SOM Biotech. The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to ...